Here is some DD for RJ and others. As usual, it is DD that he nor anyone else on this board has paid for.

First DD item; who owns the building in Hinesville, GA (and other pertinent information)

From the 10K found on the SEC/Edgars website:

http://www.sec.gov/Archives/edgar/da...

Quote 1 page F-18:

     (2)  BioAgra  leases land and a building under a ten-year lease expiring in
          February  2015,  which  requires  a  monthly lease payment of $12,000.

Quote 2 page 11:

     BioAgra  is  located  at  103  Technology Drive, Hinesville, Georgia 31313.
BioAgra  has  leased  the facility from the Liberty County Industrial Authority,
pursuant  to  an Industrial Lease Agreement, dated March 1, 2005 for a period of
10  years.  At  the  expiration  of  the  lease  term, BioAgra has the option to
purchase  the  leased premises (real estate and improvements) for $500,000.  The
facility is approximately 30,000 square feet which consists of both office space
and  a  production area and a research and development laboratory.  The facility
is  located  on  approximately  7.29  acres.

Second DD item; guidelines as to SEC reporting:

Found in Electronic Code of Federal Regulations:

http://ecfr.gpoaccess.gov/cgi/t/text...

Quote 1 under General Notes to Financial Statements

§ 210.4-08 General notes to financial statements.

(2) Summarized financial information shall be presented insofar as is practicable as of the same dates and for the same periods as the audited consolidated financial statements provided and shall include the disclosures prescribed by ?210.1?02(bb). Summarized information of subsidiaries not consolidated shall not be combined for disclosure purposes with the summarized information of 50 percent or less owned persons.

The above link also provides a tremendous amount of information and guidelines for SEC filing and regulations. If you are interested, definitely read up on reg 210.1-02

The requirement for subsidiary inclusion does not separate into what form the legal entity takes. A subsidiary is a subsidiary.

What would be good for VytaCorp is for a subsidiary that is owned > 50%, financial statements can be consolidated and profits/losses for both would go to the parent's bottom line. If we owned >50% of ExypnoTech, we would be able to report consolidated financials and VytaCorp would show revenue in excess of $1 million per last third fiscal quarter with double digit revenue growth quarter over quarter. As it is, VytaCorp owns 49% of ExypnoTech and is required to report balance sheet separately.

Third DD item - can you get samples?

RJ, you can bet your bottom dollar that you can get sample(s) if you can demonstrate a real potential usage for Agrastim, Purestim, Equiforce, etc.

When I attended the International Poultry show in Atlanta last January (2007), BioAgra had sample jars both to have tangible product and for potential customers. These jars were only a few onces each but when you consider that Agrastim costs $200+ per kilogram, a few onces is a fair amount of money worth.

With the amicable termination agreement between PBI and BioAgra, the restriction of BioAgra's sale for human consumption has been lifted. For anyone able to demonstrate to BioAgra their ability to market Purestim to the human population, samples and inventory would be available.

Bottom line is, show the need and you will get the inventory.

Hope this helps,

Kent